• Mashup Score: 5
    Long-term outcomes from the BelaRd trial and the evaluation of a VRA tool to guide belamaf dosing - 1 day(s) ago

    Evangelos Terpos, MD, PhD, University of Athens School of Medicine, Athens, Greece, discusses the results of the BelaRd trial (NCT04808037), a Phase I/II study that investigated a novel, extended dosing schedule of belantamab mafodotin (belamaf) in combination with lenalidomide and dexamethasone (Rd), in transplant-ineligible patients with newly diagnosed multiple myeloma (MM). This combination approach demonstrated promising efficacy, with no new safety signals observed. Prof. Terpos also mentions the evaluation of a Vision-Related Anamnestic (VRA) tool, a patient-reported questionnaire that captures ocular symptoms and their impact on activities of daily living. This VRA tool could aid physicians in making decisions about dosing frequency without the need for an ophthalmology examination. This interview took place at the 11th World Congress on Controversies in Multiple Myeloma (COMy) congress in Paris, France. These works are owned by Magdalen Medical Publishing (MMP) and are protect

    Source: www.vjhemonc.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      🎥 Evangelos Terpos @uoaofficial comments on the long-term outcomes from the BelaRd trial and provides insight into the evaluation of a VRA tool to guide belamaf dosing in patients with #myeloma. Watch here: 👉 https://t.co/v64aUIFeua #ASCO25 #MMSM #MultipleMyeloma #CTSM @ASCO

  • Mashup Score: 2
    Biomarkers in the era of complement inhibition for PNH - 2 day(s) ago

    Austin Kulasekararaj, MBBS, MD, MRCP, FRCPath, King’s College Hospital NHS Foundation Trust, London, UK, comments on the utility of biomarkers in the era of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), emphasizing the importance of simple and easily accessible biomarkers. Dr Kulasekararaj highlights lactate dehydrogenase (LDH) as a valuable biomarker, as well as reticulocyte count and unconjugated bilirubin levels, which can aid in monitoring patients switching from C5 inhibitors to proximal inhibitors. Clinical symptoms are also helpful, particularly for identifying cases of acute hemolysis or breakthrough hemolysis. This interview took place at the 2nd International PNH Interest Group (IPIG) Conference in Paris, France. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjhemonc.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      🎥 At #IPIG2025, @AustinKulasekar of @KingsCollegeNHS commented on the utility of biomarkers in the era of complement inhibition for the treatment of PNH, emphasizing the importance of simple & easily accessible biomarkers: 👉 https://t.co/nvG0IZtLTp 👈 #RareDisease #Hematology

  • Mashup Score: 5
    The potential use of multi-virus-specific T-cells to enhance the activity of bispecifics in lymphoma - 3 day(s) ago

    In this video, Akiva Diamond, MD, Baylor College of Medicine, Houston, TX, comments on the potential of using multi-virus-specific T-cells (MVSTs) to enhance the activity of bispecific antibodies in lymphoma treatment. Dr Diamond highlights that MVSTs, which are expanded ex vivo to target viral peptides, show significantly increased expansion and greater levels of cytokine secretion, activation, and cytotoxicity compared to regular whole blood peripheral blood mononuclear cells (PBMCs). Although these are preliminary findings, they suggest that this approach may help overcome the current limitations of bispecifics and could lead to improved outcomes for patients with lymphoma. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjhemonc.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Want to hear about the potential use of multi-virus-specific T-cells to enhance the activity of bispecifics in #lymphoma?🩸 Then check out our interesting interview with @AkivaDiamond of @BCMDeptMedicine from the recent #ASCO25 meeting: 👉 https://t.co/UDYCj0JMga #LYMsm @ASCO

  • Mashup Score: 3
    Novel targeting of S100A9 with tasquinimod in multiple myeloma - 3 day(s) ago

    Dan Vogl, MD, MSCE, University of Pennsylvania, Philadelphia, PA, comments on the potential future role of tasquinimod, an oral small-molecule inhibitor of S100A9, in the treatment landscape of multiple myeloma (MM). Dr Vogl highlights the results of a clinical trial (NCT04405167) in which tasquinimod was given as monotherapy or in combination with ixazomib, lenalidomide, and dexamethasone (IRD) in patients who were refractory to their most recently received immunomodulatory drug (IMiD)-proteasome inhibitor (PI) combination. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjhemonc.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Does the targeting of S100A9 with tasquinimod hold promise for treating #myeloma?💭🩸 At #ASCO25, Dan Vogl (@PennMedicine) presented results of a trial in which tasquinimod was given as monotherapy or combined with IRD: 👉 https://t.co/RFekwk9TrI #CTSM #MMSM #TrialUpdate @ASCO

  • Mashup Score: 4
    A Phase I study of asciminib combined with dasatinib, prednisone, and blinatumomab for Ph+ ALL - 4 day(s) ago

    Marlise Luskin, MD, MSCE, Dana-Farber Cancer Institute, Boston, MA, discusses a Phase I study (NCT03595917) that investigated the use of dasatinib, asciminib, blinatumomab, and prednisone in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Dr Luskin highlights that the results with this dual tyrosine kinase inhibitor (TKI) approach were encouraging, and she shares her excitement at the potential of providing patients with a chemotherapy-free and transplant-free therapeutic option. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjhemonc.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      A Phase I study investigated the use of dasatinib, asciminib, blinatumomab, & prednisone in patients with Ph+ ALL. We recently spoke with @LuskinMarlise of @DanaFarber to hear the results! Watch the interview here: 👉 https://t.co/gEhR3Qpuj7 #ASCO25 @ASCO #CTSM #ALLsm #Leusm

  • Mashup Score: 11
    Improving access and delivery of CAR T-cells and bispecific antibodies in the community - 4 day(s) ago

    Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, Tara Graff, DO, MS, Mission Cancer and Blood, Des Moines, IA, and Caron Jacobson, MD, Dana-Farber Cancer Institute, Boston, MA, share their perspectives on how to improve access and delivery of T-cell engaging therapies in the community. They discuss logistical barriers that need to be addressed and further comment on the importance of close collaboration between hospitals and community centers. This discussion took place at the 7th International Workshop on CAR-T and bispecifics (iwCAR-T) 2025 held in Miami, FL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjhemonc.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      🎥 At #iwCART25, @KrishPatelMD, Tara Graff, & Caron Jacobson shared their perspectives on how to improve access & delivery of T-cell engaging therapies (CAR-T and bispecifics) in the community. Watch the discussion here: 👉 https://t.co/Q5neIajxRn #HemOnc #CARTCell #ImmunoOnc

  • Mashup Score: 5
    Preventing thrombosis in patients with PNH - 5 day(s) ago

    In this video, Jeff Szer, MBBS, FRACP, Peter MacCallum Cancer Centre, Melbourne, Australia, comments on the prevention of thrombosis in patients with paroxysmal nocturnal hemoglobinuria (PNH), highlighting that terminal complement inhibition is the most effective approach. Dr Szer also mentions the controversy surrounding the use of anticoagulants in these patients, acknowledging that this therapeutic approach may be necessary in areas where complement inhibition is not readily available. This interview took place at the 2nd International PNH Interest Group (IPIG) Conference in Paris, France. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

    Source: www.vjhemonc.com
    Categories: General Medicine News
    Tweet Tweets with this article
    • Profile photo of VJHemOnc
      VJHemOnc

      Want to learn about the prevention of thrombosis in patients with PNH?🩸 Make sure to watch our recent interview from #IPIG2025 with Jeff Szer (@marrow) of @PeterMacCC in which he discusses this: 🎥 https://t.co/Aj9Rz2qMOQ #RareDisease #Hematology #Thrombosis

Load More